Hydroxychloroquine, a medication commonly used to prevent and treat malaria, has garnered significant attention in recent years due to its potential off-label use in treating certain autoimmune diseases and, more controversially, in managing COVID-19. However, its use in these contexts often requires regular eye examinations to monitor for potential retinal toxicity. This article delves into the guidelines for hydroxychloroquine eye exams, ensuring the safety and well-being of patients undergoing this treatment.

Hydroxychloroquine can accumulate in the retina over time, potentially leading to vision problems. Therefore, regular eye examinations are crucial to detect any signs of retinal damage early. The American Academy of Ophthalmology (AAO) and the National Eye Institute (NEI) have established guidelines to ensure the safe and effective use of hydroxychloroquine, which we will explore in detail.

Understanding Hydroxychloroquine Retinopathy
Hydroxychloroquine retinopathy is a progressive, dose-dependent condition that can lead to irreversible vision loss. It typically affects the macula, the part of the retina responsible for central vision. Symptoms may include decreased visual acuity, paracentral scotomas (blind spots), and color vision changes.

Risk factors for hydroxychloroquine retinopathy include daily dose, duration of therapy, age, and pre-existing retinal disease. Patients with these risk factors should have more frequent eye examinations.
Baseline Eye Exam

A baseline eye exam is recommended before starting hydroxychloroquine therapy. This exam should include a comprehensive dilated eye examination with fundus photography and automated visual field testing. This baseline assessment helps establish a reference point for future comparisons.
In patients at high risk for retinopathy (those with pre-existing retinal disease or taking a daily dose exceeding 5.0 mg/kg of actual body weight), a baseline optical coherence tomography (OCT) may also be considered.
Follow-up Eye Exams

For patients at low risk (daily dose ≤5.0 mg/kg, no pre-existing retinal disease), follow-up eye exams are recommended every 5 years. For those at medium risk (daily dose >5.0 mg/kg but ≤6.5 mg/kg), follow-up exams are recommended every 3 years. Patients at high risk should have annual eye exams.
Each follow-up exam should include a comprehensive dilated eye examination with fundus photography and automated visual field testing. OCT may also be considered in high-risk patients or if clinical suspicion of retinopathy is present.
Monitoring and Management of Hydroxychloroquine Retinopathy

Regular eye examinations allow for early detection and management of hydroxychloroquine retinopathy. If signs of retinopathy are detected, the hydroxychloroquine dose should be reduced or discontinued, depending on the severity and progression of the condition.
Close collaboration between the prescribing physician and the ophthalmologist is essential for monitoring and managing potential retinal toxicity. Patients should also be educated about the importance of regular eye examinations and the signs of hydroxychloroquine retinopathy to report to their healthcare provider.

Special Considerations: COVID-19 and Off-Label Use of Hydroxychloroquine
In the context of the COVID-19 pandemic, hydroxychloroquine has been used off-label for prophylaxis and treatment. The AAO and NEI have emphasized the importance of adhering to the established eye exam guidelines for patients receiving hydroxychloroquine for these indications.
However, given the evolving nature of the pandemic and the lack of definitive evidence supporting the use of hydroxychloroquine for COVID-19, patients and healthcare providers should carefully weigh the potential benefits and risks of this therapy and consider alternative treatments when appropriate.
In conclusion, regular eye examinations are vital for the safe and effective use of hydroxychloroquine. By adhering to the established guidelines, healthcare providers can minimize the risk of hydroxychloroquine retinopathy and ensure the best possible outcomes for their patients. As always, open communication and shared decision-making between patients and healthcare providers are essential for optimizing care.